What is InpharmD?
InpharmD operates as a provider of updated, scientifically supported data and evidence-based recommendations. The company specializes in delivering concise yet detailed information, responding rapidly to clinical questions related to pharmacy. InpharmD excels at linking conclusions from various studies, offering excellent explanations about drug uses, side effects, and research findings. While providing detailed answers, the company aims to refine its focus on conclusions, positioning itself as a valuable and accessible resource for evidence-based drug information.
How much funding has InpharmD raised?
InpharmD has raised a total of $6M across 1 funding round:
Other Financing Round
$6M
Other Financing Round (2023): $6.1M with participation from Atlanta Ventures, Y Combinator, 645 Ventures, and Qlarant
Key Investors in InpharmD
Atlanta Ventures
Atlanta Ventures is a venture capital firm focused on empowering entrepreneurs in the Southeastern United States through community, content, and capital, with a specialization in co-founding and early-stage funding for subscription-based businesses.
Y Combinator
Y Combinator is a renowned startup accelerator that provides seed funding and mentorship to early-stage companies, helping them to scale and achieve significant growth.
645 Ventures
645 Ventures is a venture capital firm that invests in seed and Series A SaaS companies, partnering with founders to drive transformation through strategic support in customer acquisition, talent, and fundraising.
What's next for InpharmD?
The recent major strategic investment signifies a pivotal moment for InpharmD, likely enabling the company to accelerate its product development, expand its market reach, and enhance its data analytics capabilities. This enterprise-level backing suggests a focus on scaling operations and solidifying its position as a leading provider of pharmaceutical data intelligence. Future growth will likely involve further integration of advanced AI for data synthesis and broader adoption within healthcare systems seeking rapid, evidence-based clinical insights.
See full InpharmD company page
